secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001654954-24-012549
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin reports FY2024 net loss $29.7M, cash $9.5M; outlines clinical milestones for obesity, DED, ED, UC
--------------------------------------------------------------------------------

- Net loss for FY2024 $29.7M ($2.02 per share) vs $24.0M ($2.21) prior year; revenue declined as Vyleesi asset sold.
- Cash and cash equivalents $9.5M at June 30, 2024; auditor includes going concern explanatory paragraph.
- Obesity Phase 2 MC4R+GLP-1 trial enrollment to complete early Q4 2024; topline results expected Q1 2025.
- DED Phase 3 MELODY-2/3 trials to start enrollment Q1 2025; topline results anticipated Q4 2025.
- Diabetic nephropathy Phase 2 BREAKOUT topline results expected Q4 2024; UC Phase 2 interim readout Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495424012549/0001654954-24-012549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495424012549/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-012549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer